Mentor Corporation (Mentor), incorporated in 1969, develops, manufactures and markets a range of products serving the aesthetic medicine market, including plastic and reconstructive surgery. Aesthetic surgery products include surgically implantable prostheses for plastic and reconstructive surgery, capital equipment and consumables used for soft tissue aspiration or body contouring (liposuction), and facial aesthetics products. The aesthetic medicine products fall into three general categories: breast implants, body contouring and other aesthetics, which includes facial aesthetics products. The Company operated in three segments: aesthetic and general surgery, surgical urology, and clinical and consumer healthcare. On May 17, 2006, it entered into a definitive purchase agreement for the sale of its surgical urology and clinical and consumer healthcare business segments (the Urology Business). On April 3, 2006, Mentor submitted a pre-market approval application to the United States Food and Drug Administration (FDA) for its Contour Profile silicone gel-filled breast implant products (CPG). On March 20, 2006, the Company signed a non-binding letter of intent with Niadyne, Inc. to distribute Niadyne's NIA 24 line of science-based cosmeceutical products. On July 28, 2005, it received an approvable letter with conditions from the FDA on its pre-market approval application for its MemoryGel round silicone gel-filled breast implants. Mentor develops, produces and markets a line of breast implants, including saline-filled implants and silicone gel-filled (MemoryGel) implants. The Company's breast implants consist of a silicone elastomer shell that is either filled during surgery with a saline solution or pre-filled during the manufacturing process with silicone gel. Its MemoryGel products come in varying degrees of cohesiveness. In addition, all of its implants have either a smooth or textured surface and are provided in a variety of sizes and shapes to meet the varying preferences of patients and surgeons. The Company carries a full line of breast reconstruction products, including the Contour Profile Tissue Expander (CPX) family of breast expanders. These expansion products, used in the first-stage of a two-stage breast reconstruction, create a pocket that will ultimately hold the breast implant that is placed in a subsequent second-stage operation. All of the CPX devices utilize Mentor's BufferZone self sealing technology and Centerscope injection port locators. It also provides for single-stage breast reconstruction procedures, with the Company's line of smooth and textured Becker implants, which are designed to be used as both an expander and a permanent implant. Mentor offers a line of extremity tissue expanders. Extremity tissue expansion involves the process of growing additional tissue for reconstruction and skin graft procedures. Some of the major applications of extremity tissue expansion include the correction of disfigurements, such as burns, large scars and congenital deformities. With respect to body contouring, the Company markets through its subsidiary, Byron Medical, Inc., a complete line of liposuction products and disposable supplies. During the fiscal year ended March 31, 2005 (fiscal 2005), Mentor established two new business lines in the aesthetics arena, which it categorizes under other aesthtics: Mentor Solutions and Facial Aesthetics. It acquired a company called Inform Solutions, and during fiscal 2005, combined it into a new business called Mentor Solutions. The Mentor Solutions group offers software, consulting and business management tools to help plastic surgeons grow their business. In the Facial Aesthetics area, Mentor launched its new dermal filler product, Puragen, in a variety of international markets, in May 2005, and has received additional international approvals. Puragen is its non-animal based, hyaluronic acid dermal filler. The Company is developing a next-generation botulinum toxin type A product based on its technology that yields a formulation designed to be purer t